HopeStage
Back to all studies
WithdrawnNCT03263533

HDAC Inhibitor Augmentation to Clozapine

Medication studyAges 18–60Schizophrenia
The study in practice

Understand this study

Who could participate?

Listed age limits: 18 years to 60 years.

Study phase
Early phase 1An early first-in-human or very early safety study, usually focused on how a treatment behaves in the body.

What to know before participating

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Things to check before joining

Study start dateEstimated: April 2017
Recruitment status
Withdrawn
Enrollment listed in the registry
0
Sponsor
Virginia Commonwealth University
Sponsor type
University
Study type
Drug
Intervention type
Medication / drug
Study phase
EARLY Phase 1An early first-in-human or very early safety study, usually focused on how a treatment behaves in the body.
Locations
Not clearly listed
Age range
From 18 Years to 60 Years
Official registry ID
NCT03263533
Official title
Show the full official title

HDAC Inhibitor Augmentation to Clozapine

Questions about this study?

The HopeStage team will email you.

Loading the security check...

Recruitment & locations

Withdrawn

Locations not listed

FAQ

Questions about this study

Who is behind this study?

The study sponsor is Virginia Commonwealth University, a university.

Does this study involve medication?

Yes. The study involves medication, including Vorinostat Oral Capsule Group 1 and Vorinostat Oral Capsule Group 2.

Who can participate?

Listed age limits: 18 years to 60 years.

Is this study still recruiting?

The registry lists this study as withdrawn.

Explore other studies

Want to find a study that may fit you better?

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.

Find a study that may fit me